We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Fenwal Signs Agreement to Improve Transfusion Safety

By LabMedica International staff writers
Posted on 21 Jul 2009
Fenwal Inc. More...
(Lake Zurich, IL, USA), a company focused on improving blood collection, separation, safety, and availability signed a five-year exclusive worldwide agreement with Verax Biomedical Inc. (Worcester, MA, USA) to market, sell, and distribute Verax's PanGenera Detection (PGD) technology.

The Verax PGD test, a rapid immunoassay, targets antigens found on the surface of a wide spectrum of common bacteria that are pathogenic to humans in high concentrations. The immunoassay consists of an easy-to-use disposable handheld device and reagents that work together to detect the presence of bacterial contaminants in platelets. The test is performed in less than 30 min. and can be used in hospitals, cancer centers, and other sites of care, as a safeguard immediately prior to transfusion.

An estimated 1 in 2,000 to 3,000 platelet units could contain bacteria, and up to 50 % of bacteria-contaminated platelets can escape detection by conventional culture testing. Bacteria can cause fatal reactions, especially in immune-compromised patients. The Verax PGD immunoassay detects bacteria in leukocyte-reduced apheresis platelets as an adjunct quality-control test following previous bacterial testing.

Verax is developing more PGD technology diagnostic tests to detect bacteria in other blood components, tissues for transplantation, and cell-based therapies. Meanwhile the technology has been cleared by the United States Food and Drug Administration (FDA; Silver Spring, MD, USA) and received the CE marking in Europe.

More than 5 million platelet doses are transfused annually worldwide. Platelets are cells in blood that help blood clot. They are transfused when platelets levels are low--as, for example, a result of illness or the adverse effect of some chemotherapy treatments.

Darrell J. Triulzi, M.D., medical director of the Institute for Transfusion Medicine and the University of Pittsburgh Medical Center's Division of Transfusion Medicine, (UPMC; Pittsburgh, PA, USA) said, "The blood center community has made progress with the implementation of culture-based tests, but these occur at the point of collection when bacteria levels can be too low for detection. A rapid, point-of-care assay, such as the Verax PGD test, takes place just prior to transfusion, which is the best time to detect bacteria levels in platelets and provides a more comprehensive strategy for patient safety."

Related Links:
Fenwal Inc.
Verax Biomedical Inc.
United States Food and Drug Administration
University of Pittsburgh Medical Center



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
New
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.